-
Nintedanib: An ATRX-Aware Research Strategy
2026-09-11
Nintedanib (BIBF 1120) is more than a broad angiokinase inhibitor: it can serve as a genotype-aware probe in glioma and tumor-microenvironment studies. This article translates ATRX-dependent drug sensitivity into practical assay design, combination testing, and interpretation guidelines.
-
HyperScribe™ Poly (A) Tailing Kit Workflow
2026-09-11
Build more consistent capped, polyadenylated RNA for transfection experiments and micro-injection by combining E. coli Poly (A) Polymerase with a controlled post-transcriptional workflow. This guide connects tail-length optimization with metabolic-expression assays inspired by the TCAIM–OGDH reference study, while clearly separating established product capabilities from practical recommendations.
-
DiscoveryProbe Protease Inhibitor Library: Assay Logic
2026-09-10
The DiscoveryProbe Protease Inhibitor Library supports more than compound discovery: it enables pathway localization through complementary biochemical and cellular assays. This article translates a plant chemical-screening study into a rigorous framework for protease activity modulation, apoptosis assay design, cancer research, and infectious disease research.
-
O-Propargyl-Puromycin (OPP) in B-Cell Translation
2026-09-10
O-propargyl-puromycin (OPP) turns transient translation into a chemically addressable readout for protein synthesis measurement in cells. This article explains how to interpret OPP labeling within the Pcbp1–mitochondrial integrity pathway while distinguishing translation flux from protein abundance and mechanism.
-
LL-37 Mimetics: Biocidal and Antibiofilm Selectivity
2026-09-09
Luo et al. compared the human host-defense peptide LL-37 with the truncated mimetics KE-18 and KR-12 across Candida albicans, Staphylococcus aureus, and Escherichia coli. The study shows that antimicrobial potency and antibiofilm activity can diverge substantially, highlighting peptide-specific effects on biofilm prevention, inhibition, and cell-envelope targets.
-
RWJ 67657: From Cytokine Blockade to Signal Reset
2026-09-09
RWJ 67657 offers translational researchers a selective way to interrogate p38α/β-driven cytokine biology while preserving much of the broader T-cell response. This article connects its established TNF-alpha phenotype with emerging evidence that kinase conformation can influence phosphatase-driven signal termination, creating a more rigorous framework for inflammatory disease research.
-
Telatinib Workflow for Angiogenesis Research
2026-09-08
Telatinib (BAY 57-9352) supports mechanism-aware studies that connect receptor kinase inhibition with tumor-cell invasion and endothelial tube formation. This workflow emphasizes dosing discipline, target attribution, combination analysis, and troubleshooting beyond a simple viability readout.
-
Measuring Drug Response Beyond Viability Assays
2026-09-07
Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability to separate proliferative arrest from actual cell killing in cancer drug studies. Its central implication is that time-resolved, multidimensional response measurements can improve interpretation of anticancer compound activity beyond a single viability value.
-
Chlorambucil: Interpreting DNA Damage Assays
2026-09-07
Chlorambucil is a nitrogen mustard alkylating agent whose delayed DNA damage can produce very different viability and cell-death readouts. This guide applies evidence from Schwartz’s cancer-assay research to build a more rigorous, time-resolved framework for interpreting chlorambucil experiments.
-
Firefly Luciferase mRNA: Workflow & Optimization
2026-09-05
Build more interpretable gene expression, cell viability, and delivery studies with a capped, 5-moU-modified bioluminescent reporter. This practical guide connects assay setup with the metal-mediated mRNA enrichment strategy reported in Nature Communications, while separating product performance from formulation effects.
-
Rosiglitazone in Adipose Thermogenesis Workflows
2026-09-05
Rosiglitazone, also known as Brl-49653, provides a controlled pharmacological entry point for PPARγ activation in adipogenesis, insulin sensitivity modulation, and beige-fat experiments. This workflow pairs dose-controlled PPARγ agonism with the SETD7 browning model to separate adipocyte formation from thermogenic remodeling.
-
NADH: Redox Biology and Research Workflows
2026-09-04
NADH, or reduced nicotinamide adenine dinucleotide, is an electron-donating coenzyme that connects glycolysis, the TCA cycle, and mitochondrial respiration. This article defines its biochemical role, evidence boundaries, storage requirements, and practical use in mitochondrial electron transport chain research and related disease-model workflows.
-
In Vitro Drug Response: Viability and Cell Death
2026-09-04
Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that these commonly interchanged readouts capture different contributions from proliferative arrest and cell death. The findings support time-aware, metric-specific in vitro drug testing and caution against interpreting a single viability endpoint as a direct measure of cytotoxicity.
-
Pazopanib: Biomarker-Aware RTK Assay Design
2026-09-03
Pazopanib and GW-786034 offer a powerful framework for studying receptor tyrosine kinase dependence. This article shows how ATRX status, pathway readouts, and assay context can improve cancer research interpretation beyond simple viability measurements.
-
Mestranol and Reversible Lysosomal Stress in Microglia
2026-09-02
A 2026 Aquatic Toxicology study identifies mestranol as an inducer of a reversible lysosomal storage–like state in zebrafish microglia. The work separates impaired intracellular digestion from phagocytic uptake and neuronal apoptosis, providing a live model for studying environmental estrogen neuroimmunotoxicity.